nemolizumab
galderma
['nemolizumab']
aad 2023: late-breaking phase iii results demonstrate nemolizumab s significant impact on prurigo nodularis - -
MD MSC CPDS https://t.co/YL6HxBReRh https://t.co/kePCRsN4Gw  https://t.co/t7oxnCVsEI  #cardiology  #AI #informatics #healthcare #innovation #Data